A Multidisciplinary Approach for Patients with Preexisting Lung Diseases and Immune Checkpoint Inhibitor Toxicities

This commentary outlines the strategy employed by a multidisciplinary immune‐related toxicity team to evaluate patients who may be at high risk for the development of immune‐related toxicity, in particular, those with preexisting lung conditions and subsequent immune‐related pneumonitis.